Sirna Posts Higher Q2 Revenues, Lower Losses

Sirna Therapeutics reported this week a sharp increase in second-quarter revenues, which helped to push down the company's losses.

The company posted revenues of $1.5 million in the quarter, up from $454,000 in the year-ago period, reflecting a surge in fees received from contract manufacturing services.

Sirna's second-quarter net loss arrived at $5.9 million, or $0.14 per share, versus $6.3 million, or $0.18 per share a year earlier.